Cleveland

Author Archives

JACKPOT DIGITAL “JPOTF”

Jackpot Digital OTC JPOTF TSXV JP Interesting but very speculative but near bottom of price range. I do like the business model. Please do your own due diligence. The Company’s primary business model is the licensing of its ETG tables to casino operators in exchange for a monthly recurring revenue stream. LOL from website—watch it […]

Anatabloc at GNC Star Scientific

I have been on Anatabloc for two months and it has changed my life completely. Anatabloc nutraceutical supplement available at GNC Thyroid Thyroid / Thyroiditis Overview In the USA alone over 70 million THYROID prescriptions are written at a value of about $2 billion; it’s the 4th most prescribed prescriptions for any disease. In the […]

Recent Author Comments

On Microblog: Discussion page for Arch Therapeutics (ARTH)
JohnM How do you interpret the above? Does it not help explain a lot?[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Arch Therapeutics (ARTH) Versus Closure Medical Corporation Overview: Arch has been compared to Closure Medical which was acquired by Johnson & Johnson for $ 370 million in March 2005.  Arch’s present market cap is only 15% of Closure’s acquisit[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
$ARTH Long Let me do a verbal interpretation of the above because ARTH is following the exact template of Closure. Closure did the JNJ Marketing arrangement BEFORE going public AND before getting regulatory approvals. This juiced their IPO event having [...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
$ARTH Long This is so interesting. Closure Medical---Marketing Agreements--Note Up Front licensing fees BEFORE regulatory approvals "On March 20, 1996, the Company entered into an eight-year exclusiv supply and distribution rights agreement with Ethicon[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Charles Mary Apple Thank you so much for your very kind comments. For years I have tried very hard to be helpful. I just want to help people do their own due diligence. My due diligence is never ever done. I never cared whether you own or not. That is your[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
JMBanks Good question. I am working on it. Thanks[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Oh Jeffrey M here, Dangerb407 at Seeking Alpha and just plain Jeffrey everywhere else. My you leave a wide path. So much misinformation and total nonsense all in the attempt to stifle any real discussion of Arch. For example you posted at one of the othe[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
$ARTH Presentation LD Micro 6/4/19 by Dr. Terry Norchi plus my comments 1) On verge of commercialization. How many of your biotech investment positions are in the same situation? What is the risk here?   2) Planned revenue stream by End of Year. Buil[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Daniel L. Kapp MD Chief of Surgery, Palm Beach Gardens Medical Center Board Certified Plastic Surgeon Director Jupiter Wound Care http://www.drdanielkapp.com/meet-dr-kapp.php "The video illustrates the use of AC5TM Topical Gel in porcine surgical w[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Doc As I said several months ago to you is that Dr. Norchi will talk to you directly as a fellow doctor. Why not get answers from him? 617-431-2316 Please share what you find out. Thanks.[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
$ARTH 3M to Buy Wound-Care Company Deal for Acelity has a total enterprise value of about $6.7 billion https://www.wsj.com/articles/3m-to-buy-acelity-for-enterprise-value-of-6-7-billion-11556795031 By Colin Kellaher Updated May 2, 2019 10:46 a.m. E[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Hi Todd This should pick up a lot of momentum. Heck Norchi has been thinking of this commercialization moment since 2006. I am hoping it is JNJ and we hear in early 2019. However it maybe after the CE Mark. I am also hoping for up front payment. H[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Slide Presentation https://tinyurl.com/yczzdtat Conference Presentation https://tinyurl.com/ybmh96r5 IMHO Norchi's Best[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
ARTH: All Aboard! Next Stop AC5 510k Decision https://tinyurl.com/ycut7397[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Yelpik I suggested drbonz call Dr. Norchi directly. We have not heard back. Most of the 50 or so patents are new within the last three years. The oldest patents are irrelevant because of the significant R&D strides made by $ARTH. Suggest you contact [...]
On Microblog: Club house for Politics, Religion, etc. (volume 8)
Shocking. Attorney Joe deGenova is the best in class.[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
DB As a doctor/surgeon/shareholder why not call Dr. Norchi directly and ask questions? I know he would love to talk with you. You can give perspective that none of us can. You are the kind of shareholder ARTH would love to attract. Dhillon was there sol[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
$ARTH Agree. I could talk for days on that presentation. Let the numbers speak. ARTH capital raised since inception  $ 29,978,723 ARTH capital spent since inception $ 23,489,622 ARTH Cash 6/30/18 $ 6,489,101 Cash % of amount spent since [...]
On Microblog: Scandium, Cobalt, and Water Purification: Clean Teq Holdings,Volume 2, 2018
CTEQF This is extremely disappointing that Marin would pull up stakes. As I have stated these Australia companies with Billion +/- share fully diluted shares outstanding are tough nuts. From Marin Katusa... Clean Teq (CLQ.TO) We are removing Cle[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
STM I am working on several projects and will get back to this. My computer screens focus on this now. Thanks.[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

Connect with Travis

website designed by Gravity Switch